Startup Parabilis Medicines has raised $305 million in new funding. These funds are intended to help bring the company's main drug for various types of cancer into the final phase of clinical testing. The company operates in the field of oncology drug development. The company's CEO is considering preparing an initial public offering (IPO). The goal of an IPO would be to enter the stock market and raise additional capital for development. The article does not list the specific name of the drug or the exact types of cancer it targets.